Review



cd3 microbeads  (Miltenyi Biotec)


Bioz Verified Symbol Miltenyi Biotec is a verified supplier
Bioz Manufacturer Symbol Miltenyi Biotec manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 96

    Structured Review

    Miltenyi Biotec cd3 microbeads
    a , Distribution of EBV latency programs among EBV⁺ B cells in healthy controls (HC) and by disease group and treatment. EBV⁺ B cells from healthy controls were entirely Latency 0/I. Latency 0 and Latency I are shown as a single category because they are separated only by detection of EBNA1, which is depth-sensitive at these coverages. b , Differential expression between EBV⁺ B cells and depth-matched EBV⁻ B cells from the same libraries, plotted as the log₂ fold change against the −log₁₀ P value of a patient-level test. The dotted line marks P = 0.05; colored points are the genes shown in c and the six with the strongest evidence are labeled. c , log₂ fold change for thirteen survival-associated genes in EBV⁺ versus depth-matched EBV⁻ B cells, grouped as survival and NF-κB, anti-apoptotic, death-receptor inhibitor and complement inhibitor. Exact P values are given beside each bar, in black where P < 0.05 and in gray otherwise. Because the comparator cells are matched on sequencing depth, these are compositional comparisons: a gene is elevated relative to the rest of the transcriptome in the same cells, and a uniform increase in transcriptional output would not register as a difference. P values are from a one-sample two-sided t-test on per-library log₂ fold changes (n = 11 libraries). d , In vitro cytotoxicity of the anti-CD20 mAbs rituximab, obinutuzumab and ocrelizumab, the anti-CD19 mAb inebilizumab, CD19-CAR T cells, and the CD19 T-cell engager blinatumomab (CD19 × <t>CD3),</t> against EBV⁻ targets (primary B cells and Ramos cells) and EBV⁺ lymphoblastoid cell lines (LCL-1 and LCL-2) across NK cell, CAR T-cell, or T cell effector-to-target ratios. Anti-CD20 and anti-CD19 antibodies showed reduced cytotoxicity against EBV⁺ relative to EBV⁻ targets at every ratio, whereas CD19-CAR T cells and blinatumomab differed only at the intermediate 2:1 ratio. Data are mean ± s.e.m.; differences between EBV⁺ and EBV⁻ targets were assessed by two-way analysis of variance with Sidak’s correction, with exact P values shown at each ratio and ns denoting P ≥ 0.05.
    Cd3 Microbeads, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 561 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd3+microbeads/CD3+MicroBeads%2C+human/bio_rxiv__64898__2026__10__24__761515-173-12-15
    Average 96 stars, based on 561 article reviews
    cd3 microbeads - by Bioz Stars, 2026-11
    96/100 stars

    Images

    1) Product Images from "CD19-CAR T-cell therapy resets the EBV + autoreactive B cell repertoire in autoimmune disease"

    Article Title: CD19-CAR T-cell therapy resets the EBV + autoreactive B cell repertoire in autoimmune disease

    Journal: bioRxiv

    doi: 10.64898/2026.10.24.761515

    a , Distribution of EBV latency programs among EBV⁺ B cells in healthy controls (HC) and by disease group and treatment. EBV⁺ B cells from healthy controls were entirely Latency 0/I. Latency 0 and Latency I are shown as a single category because they are separated only by detection of EBNA1, which is depth-sensitive at these coverages. b , Differential expression between EBV⁺ B cells and depth-matched EBV⁻ B cells from the same libraries, plotted as the log₂ fold change against the −log₁₀ P value of a patient-level test. The dotted line marks P = 0.05; colored points are the genes shown in c and the six with the strongest evidence are labeled. c , log₂ fold change for thirteen survival-associated genes in EBV⁺ versus depth-matched EBV⁻ B cells, grouped as survival and NF-κB, anti-apoptotic, death-receptor inhibitor and complement inhibitor. Exact P values are given beside each bar, in black where P < 0.05 and in gray otherwise. Because the comparator cells are matched on sequencing depth, these are compositional comparisons: a gene is elevated relative to the rest of the transcriptome in the same cells, and a uniform increase in transcriptional output would not register as a difference. P values are from a one-sample two-sided t-test on per-library log₂ fold changes (n = 11 libraries). d , In vitro cytotoxicity of the anti-CD20 mAbs rituximab, obinutuzumab and ocrelizumab, the anti-CD19 mAb inebilizumab, CD19-CAR T cells, and the CD19 T-cell engager blinatumomab (CD19 × CD3), against EBV⁻ targets (primary B cells and Ramos cells) and EBV⁺ lymphoblastoid cell lines (LCL-1 and LCL-2) across NK cell, CAR T-cell, or T cell effector-to-target ratios. Anti-CD20 and anti-CD19 antibodies showed reduced cytotoxicity against EBV⁺ relative to EBV⁻ targets at every ratio, whereas CD19-CAR T cells and blinatumomab differed only at the intermediate 2:1 ratio. Data are mean ± s.e.m.; differences between EBV⁺ and EBV⁻ targets were assessed by two-way analysis of variance with Sidak’s correction, with exact P values shown at each ratio and ns denoting P ≥ 0.05.
    Figure Legend Snippet: a , Distribution of EBV latency programs among EBV⁺ B cells in healthy controls (HC) and by disease group and treatment. EBV⁺ B cells from healthy controls were entirely Latency 0/I. Latency 0 and Latency I are shown as a single category because they are separated only by detection of EBNA1, which is depth-sensitive at these coverages. b , Differential expression between EBV⁺ B cells and depth-matched EBV⁻ B cells from the same libraries, plotted as the log₂ fold change against the −log₁₀ P value of a patient-level test. The dotted line marks P = 0.05; colored points are the genes shown in c and the six with the strongest evidence are labeled. c , log₂ fold change for thirteen survival-associated genes in EBV⁺ versus depth-matched EBV⁻ B cells, grouped as survival and NF-κB, anti-apoptotic, death-receptor inhibitor and complement inhibitor. Exact P values are given beside each bar, in black where P < 0.05 and in gray otherwise. Because the comparator cells are matched on sequencing depth, these are compositional comparisons: a gene is elevated relative to the rest of the transcriptome in the same cells, and a uniform increase in transcriptional output would not register as a difference. P values are from a one-sample two-sided t-test on per-library log₂ fold changes (n = 11 libraries). d , In vitro cytotoxicity of the anti-CD20 mAbs rituximab, obinutuzumab and ocrelizumab, the anti-CD19 mAb inebilizumab, CD19-CAR T cells, and the CD19 T-cell engager blinatumomab (CD19 × CD3), against EBV⁻ targets (primary B cells and Ramos cells) and EBV⁺ lymphoblastoid cell lines (LCL-1 and LCL-2) across NK cell, CAR T-cell, or T cell effector-to-target ratios. Anti-CD20 and anti-CD19 antibodies showed reduced cytotoxicity against EBV⁺ relative to EBV⁻ targets at every ratio, whereas CD19-CAR T cells and blinatumomab differed only at the intermediate 2:1 ratio. Data are mean ± s.e.m.; differences between EBV⁺ and EBV⁻ targets were assessed by two-way analysis of variance with Sidak’s correction, with exact P values shown at each ratio and ns denoting P ≥ 0.05.

    Techniques Used: Quantitative Proteomics, Labeling, Sequencing, In Vitro, Analysis, Bioprocessing

    Related Articles

    Labeling:

    Article Title: Small RNA sequencing identifies T cell-derived tsRNAs as novel biomarkers for diagnosis and clinical assessment of rheumatoid arthritis.
    Article Snippet: Objective: The functional role of tRNA-derived small RNAs (tsRNAs) in CD3+ T lymphocytes in rheumatoid arthritis (RA) remains unclear.. This study aimed to characterize their expression profile and evaluate their biomarker potential in RA.. Methods: Small RNA sequencing of CD3+ T lymphocytes was performed to profile tsRNA expression.

    Isolation:

    Article Title: Small RNA sequencing identifies T cell-derived tsRNAs as novel biomarkers for diagnosis and clinical assessment of rheumatoid arthritis.
    Article Snippet: Objective: The functional role of tRNA-derived small RNAs (tsRNAs) in CD3+ T lymphocytes in rheumatoid arthritis (RA) remains unclear.. This study aimed to characterize their expression profile and evaluate their biomarker potential in RA.. Methods: Small RNA sequencing of CD3+ T lymphocytes was performed to profile tsRNA expression.

    Article Title: Biparatopic CAR-T cells targeting full-length MUC1 and truncated MUC1β circumvent MUC1α shedding in ovarian cancer
    Article Snippet: .. Human primary T cells were isolated from healthy donor-derived peripheral blood mononuclear cells (PBMCs) using CD3 microbeads (Miltenyi Biotec, 130–050-101) and activated with CD3/CD28 Dynabeads (Gibco, 40203D) for 24 hours. ..

    Article Title: GAS5 Downregulation Promotes the Progression of Triple-Negative Breast Cancer by Regulating Tumor Cells-MDSCs Crosstalk.
    Article Snippet: .. To functionally validate the immunosuppressive capacity of isolated MDSC subsets, autologous CD3+T cells were purified from healthy donor PBMCs by positive selection using CD3 microbeads (Miltenyi Biotec, Shanghai, China) according to the manufacturer’s instructions. .. Purified CD3+T cells were then stimulated with anti-CD3/CD28 Dynabeads (Thermo Fisher Scientific, Waltham, MA, USA) at a bead-to-cell ratio of 1:1 in complete RPMI 1640 medium supplemented with 10% FBS, 100 U/mL penicillin, 100 μg/mL streptomycin, and 20 U/mL human IL-2 (PeproTech, Suzhou, China).

    Article Title: Mitochondria transfer via tunneling nanotubes drives macrophage immunosuppression and metabolic reprogramming in pediatric AML.
    Article Snippet: .. Human CD3+ T cells killing assay CD3+ T cells were isolated from PBMCs by MACS using CD3 MicroBeads (Miltenyi Biotec, Leiden, The Netherlands) and used as effector cells. ..

    Mass Spectrometry:

    Article Title: Small RNA sequencing identifies T cell-derived tsRNAs as novel biomarkers for diagnosis and clinical assessment of rheumatoid arthritis.
    Article Snippet: Objective: The functional role of tRNA-derived small RNAs (tsRNAs) in CD3+ T lymphocytes in rheumatoid arthritis (RA) remains unclear.. This study aimed to characterize their expression profile and evaluate their biomarker potential in RA.. Methods: Small RNA sequencing of CD3+ T lymphocytes was performed to profile tsRNA expression.

    Magnetic Cell Separation:

    Article Title: CD19-CAR T-cell therapy resets the EBV + autoreactive B cell repertoire in autoimmune disease
    Article Snippet: .. T cells were depleted from PBMCs by magnetic-activated cell sorting (MACS) using CD3 MicroBeads (Cat#130-050-101; Miltenyi Biotec). ..

    Article Title: Mitochondria transfer via tunneling nanotubes drives macrophage immunosuppression and metabolic reprogramming in pediatric AML.
    Article Snippet: .. Human CD3+ T cells killing assay CD3+ T cells were isolated from PBMCs by MACS using CD3 MicroBeads (Miltenyi Biotec, Leiden, The Netherlands) and used as effector cells. ..

    Purification:

    Article Title: GAS5 Downregulation Promotes the Progression of Triple-Negative Breast Cancer by Regulating Tumor Cells-MDSCs Crosstalk.
    Article Snippet: .. To functionally validate the immunosuppressive capacity of isolated MDSC subsets, autologous CD3+T cells were purified from healthy donor PBMCs by positive selection using CD3 microbeads (Miltenyi Biotec, Shanghai, China) according to the manufacturer’s instructions. .. Purified CD3+T cells were then stimulated with anti-CD3/CD28 Dynabeads (Thermo Fisher Scientific, Waltham, MA, USA) at a bead-to-cell ratio of 1:1 in complete RPMI 1640 medium supplemented with 10% FBS, 100 U/mL penicillin, 100 μg/mL streptomycin, and 20 U/mL human IL-2 (PeproTech, Suzhou, China).

    Selection:

    Article Title: GAS5 Downregulation Promotes the Progression of Triple-Negative Breast Cancer by Regulating Tumor Cells-MDSCs Crosstalk.
    Article Snippet: .. To functionally validate the immunosuppressive capacity of isolated MDSC subsets, autologous CD3+T cells were purified from healthy donor PBMCs by positive selection using CD3 microbeads (Miltenyi Biotec, Shanghai, China) according to the manufacturer’s instructions. .. Purified CD3+T cells were then stimulated with anti-CD3/CD28 Dynabeads (Thermo Fisher Scientific, Waltham, MA, USA) at a bead-to-cell ratio of 1:1 in complete RPMI 1640 medium supplemented with 10% FBS, 100 U/mL penicillin, 100 μg/mL streptomycin, and 20 U/mL human IL-2 (PeproTech, Suzhou, China).

    Transplantation Assay:

    Article Title: Cord blood-derived natural killer cells engineered with a novel, highaffinity chimeric antigen receptor can eliminate acute myeloid leukemia cells with minimal C-type lectin-like molecule-1 expression.
    Article Snippet: After thawing, the cells were resuspended in RPMI 1640 (Nacalai Tesque) supplemented with 10% FBS (Nichirei) and 80 U/mL DNase I (SigmaAldrich). .. CD3+ cells were depleted using CD3 MicroBeads (Miltenyi Biotec), and the remaining cells were immediately transplanted into immunodeficient mice via intra–bone marrow transplantation (iBMT) without prior in vitro culture. ..

    In Vitro:

    Article Title: Cord blood-derived natural killer cells engineered with a novel, highaffinity chimeric antigen receptor can eliminate acute myeloid leukemia cells with minimal C-type lectin-like molecule-1 expression.
    Article Snippet: After thawing, the cells were resuspended in RPMI 1640 (Nacalai Tesque) supplemented with 10% FBS (Nichirei) and 80 U/mL DNase I (SigmaAldrich). .. CD3+ cells were depleted using CD3 MicroBeads (Miltenyi Biotec), and the remaining cells were immediately transplanted into immunodeficient mice via intra–bone marrow transplantation (iBMT) without prior in vitro culture. ..



    Similar Products

    96
    Miltenyi Biotec cd3 microbeads
    a , Distribution of EBV latency programs among EBV⁺ B cells in healthy controls (HC) and by disease group and treatment. EBV⁺ B cells from healthy controls were entirely Latency 0/I. Latency 0 and Latency I are shown as a single category because they are separated only by detection of EBNA1, which is depth-sensitive at these coverages. b , Differential expression between EBV⁺ B cells and depth-matched EBV⁻ B cells from the same libraries, plotted as the log₂ fold change against the −log₁₀ P value of a patient-level test. The dotted line marks P = 0.05; colored points are the genes shown in c and the six with the strongest evidence are labeled. c , log₂ fold change for thirteen survival-associated genes in EBV⁺ versus depth-matched EBV⁻ B cells, grouped as survival and NF-κB, anti-apoptotic, death-receptor inhibitor and complement inhibitor. Exact P values are given beside each bar, in black where P < 0.05 and in gray otherwise. Because the comparator cells are matched on sequencing depth, these are compositional comparisons: a gene is elevated relative to the rest of the transcriptome in the same cells, and a uniform increase in transcriptional output would not register as a difference. P values are from a one-sample two-sided t-test on per-library log₂ fold changes (n = 11 libraries). d , In vitro cytotoxicity of the anti-CD20 mAbs rituximab, obinutuzumab and ocrelizumab, the anti-CD19 mAb inebilizumab, CD19-CAR T cells, and the CD19 T-cell engager blinatumomab (CD19 × <t>CD3),</t> against EBV⁻ targets (primary B cells and Ramos cells) and EBV⁺ lymphoblastoid cell lines (LCL-1 and LCL-2) across NK cell, CAR T-cell, or T cell effector-to-target ratios. Anti-CD20 and anti-CD19 antibodies showed reduced cytotoxicity against EBV⁺ relative to EBV⁻ targets at every ratio, whereas CD19-CAR T cells and blinatumomab differed only at the intermediate 2:1 ratio. Data are mean ± s.e.m.; differences between EBV⁺ and EBV⁻ targets were assessed by two-way analysis of variance with Sidak’s correction, with exact P values shown at each ratio and ns denoting P ≥ 0.05.
    Cd3 Microbeads, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd3+microbeads/CD3+MicroBeads%2C+human/bio_rxiv__64898__2026__10__24__761515-173-12-15
    Average 96 stars, based on 1 article reviews
    cd3 microbeads - by Bioz Stars, 2026-11
    96/100 stars
      Buy from Supplier

    97
    Miltenyi Biotec anti cd3 cd28 microbeads
    a , Distribution of EBV latency programs among EBV⁺ B cells in healthy controls (HC) and by disease group and treatment. EBV⁺ B cells from healthy controls were entirely Latency 0/I. Latency 0 and Latency I are shown as a single category because they are separated only by detection of EBNA1, which is depth-sensitive at these coverages. b , Differential expression between EBV⁺ B cells and depth-matched EBV⁻ B cells from the same libraries, plotted as the log₂ fold change against the −log₁₀ P value of a patient-level test. The dotted line marks P = 0.05; colored points are the genes shown in c and the six with the strongest evidence are labeled. c , log₂ fold change for thirteen survival-associated genes in EBV⁺ versus depth-matched EBV⁻ B cells, grouped as survival and NF-κB, anti-apoptotic, death-receptor inhibitor and complement inhibitor. Exact P values are given beside each bar, in black where P < 0.05 and in gray otherwise. Because the comparator cells are matched on sequencing depth, these are compositional comparisons: a gene is elevated relative to the rest of the transcriptome in the same cells, and a uniform increase in transcriptional output would not register as a difference. P values are from a one-sample two-sided t-test on per-library log₂ fold changes (n = 11 libraries). d , In vitro cytotoxicity of the anti-CD20 mAbs rituximab, obinutuzumab and ocrelizumab, the anti-CD19 mAb inebilizumab, CD19-CAR T cells, and the CD19 T-cell engager blinatumomab (CD19 × <t>CD3),</t> against EBV⁻ targets (primary B cells and Ramos cells) and EBV⁺ lymphoblastoid cell lines (LCL-1 and LCL-2) across NK cell, CAR T-cell, or T cell effector-to-target ratios. Anti-CD20 and anti-CD19 antibodies showed reduced cytotoxicity against EBV⁺ relative to EBV⁻ targets at every ratio, whereas CD19-CAR T cells and blinatumomab differed only at the intermediate 2:1 ratio. Data are mean ± s.e.m.; differences between EBV⁺ and EBV⁻ targets were assessed by two-way analysis of variance with Sidak’s correction, with exact P values shown at each ratio and ns denoting P ≥ 0.05.
    Anti Cd3 Cd28 Microbeads, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd3+microbeads/Treg+Suppression+Inspector%2C+human/pmc13771488-92-0-5
    Average 97 stars, based on 1 article reviews
    anti cd3 cd28 microbeads - by Bioz Stars, 2026-11
    97/100 stars
      Buy from Supplier

    96
    Miltenyi Biotec anti human cd3 microbeads
    a , Distribution of EBV latency programs among EBV⁺ B cells in healthy controls (HC) and by disease group and treatment. EBV⁺ B cells from healthy controls were entirely Latency 0/I. Latency 0 and Latency I are shown as a single category because they are separated only by detection of EBNA1, which is depth-sensitive at these coverages. b , Differential expression between EBV⁺ B cells and depth-matched EBV⁻ B cells from the same libraries, plotted as the log₂ fold change against the −log₁₀ P value of a patient-level test. The dotted line marks P = 0.05; colored points are the genes shown in c and the six with the strongest evidence are labeled. c , log₂ fold change for thirteen survival-associated genes in EBV⁺ versus depth-matched EBV⁻ B cells, grouped as survival and NF-κB, anti-apoptotic, death-receptor inhibitor and complement inhibitor. Exact P values are given beside each bar, in black where P < 0.05 and in gray otherwise. Because the comparator cells are matched on sequencing depth, these are compositional comparisons: a gene is elevated relative to the rest of the transcriptome in the same cells, and a uniform increase in transcriptional output would not register as a difference. P values are from a one-sample two-sided t-test on per-library log₂ fold changes (n = 11 libraries). d , In vitro cytotoxicity of the anti-CD20 mAbs rituximab, obinutuzumab and ocrelizumab, the anti-CD19 mAb inebilizumab, CD19-CAR T cells, and the CD19 T-cell engager blinatumomab (CD19 × <t>CD3),</t> against EBV⁻ targets (primary B cells and Ramos cells) and EBV⁺ lymphoblastoid cell lines (LCL-1 and LCL-2) across NK cell, CAR T-cell, or T cell effector-to-target ratios. Anti-CD20 and anti-CD19 antibodies showed reduced cytotoxicity against EBV⁺ relative to EBV⁻ targets at every ratio, whereas CD19-CAR T cells and blinatumomab differed only at the intermediate 2:1 ratio. Data are mean ± s.e.m.; differences between EBV⁺ and EBV⁻ targets were assessed by two-way analysis of variance with Sidak’s correction, with exact P values shown at each ratio and ns denoting P ≥ 0.05.
    Anti Human Cd3 Microbeads, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd3+microbeads/CD3+MicroBeads%2C+human/10__1158_slash_0008___5472__can___26___1157-80-13-16
    Average 96 stars, based on 1 article reviews
    anti human cd3 microbeads - by Bioz Stars, 2026-11
    96/100 stars
      Buy from Supplier

    93
    Miltenyi Biotec cd3 microbead kit
    ( A-C ) Flow cytometry analysis of <t>CD3</t> + and CD11b + fractions using the indicated antibodies. ( D-F ) Representative images (bottom) show microglia, <t>CD3</t> + <t>T</t> <t>cells,</t> and splenic myeloid cells 7 days after culture following isolation from the brain and spleen (Scale: 20x). Abbreviations: SMCs = spleen myeloid cells; MG = microglia. Please click here to view a larger version of this figure .
    Cd3 Microbead Kit, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd3+microbeads/CD3+MicroBead+Kit%2C+non-human+primate/pmc13616112-376-0-6
    Average 93 stars, based on 1 article reviews
    cd3 microbead kit - by Bioz Stars, 2026-11
    93/100 stars
      Buy from Supplier

    Image Search Results


    a , Distribution of EBV latency programs among EBV⁺ B cells in healthy controls (HC) and by disease group and treatment. EBV⁺ B cells from healthy controls were entirely Latency 0/I. Latency 0 and Latency I are shown as a single category because they are separated only by detection of EBNA1, which is depth-sensitive at these coverages. b , Differential expression between EBV⁺ B cells and depth-matched EBV⁻ B cells from the same libraries, plotted as the log₂ fold change against the −log₁₀ P value of a patient-level test. The dotted line marks P = 0.05; colored points are the genes shown in c and the six with the strongest evidence are labeled. c , log₂ fold change for thirteen survival-associated genes in EBV⁺ versus depth-matched EBV⁻ B cells, grouped as survival and NF-κB, anti-apoptotic, death-receptor inhibitor and complement inhibitor. Exact P values are given beside each bar, in black where P < 0.05 and in gray otherwise. Because the comparator cells are matched on sequencing depth, these are compositional comparisons: a gene is elevated relative to the rest of the transcriptome in the same cells, and a uniform increase in transcriptional output would not register as a difference. P values are from a one-sample two-sided t-test on per-library log₂ fold changes (n = 11 libraries). d , In vitro cytotoxicity of the anti-CD20 mAbs rituximab, obinutuzumab and ocrelizumab, the anti-CD19 mAb inebilizumab, CD19-CAR T cells, and the CD19 T-cell engager blinatumomab (CD19 × CD3), against EBV⁻ targets (primary B cells and Ramos cells) and EBV⁺ lymphoblastoid cell lines (LCL-1 and LCL-2) across NK cell, CAR T-cell, or T cell effector-to-target ratios. Anti-CD20 and anti-CD19 antibodies showed reduced cytotoxicity against EBV⁺ relative to EBV⁻ targets at every ratio, whereas CD19-CAR T cells and blinatumomab differed only at the intermediate 2:1 ratio. Data are mean ± s.e.m.; differences between EBV⁺ and EBV⁻ targets were assessed by two-way analysis of variance with Sidak’s correction, with exact P values shown at each ratio and ns denoting P ≥ 0.05.

    Journal: bioRxiv

    Article Title: CD19-CAR T-cell therapy resets the EBV + autoreactive B cell repertoire in autoimmune disease

    doi: 10.64898/2026.10.24.761515

    Figure Lengend Snippet: a , Distribution of EBV latency programs among EBV⁺ B cells in healthy controls (HC) and by disease group and treatment. EBV⁺ B cells from healthy controls were entirely Latency 0/I. Latency 0 and Latency I are shown as a single category because they are separated only by detection of EBNA1, which is depth-sensitive at these coverages. b , Differential expression between EBV⁺ B cells and depth-matched EBV⁻ B cells from the same libraries, plotted as the log₂ fold change against the −log₁₀ P value of a patient-level test. The dotted line marks P = 0.05; colored points are the genes shown in c and the six with the strongest evidence are labeled. c , log₂ fold change for thirteen survival-associated genes in EBV⁺ versus depth-matched EBV⁻ B cells, grouped as survival and NF-κB, anti-apoptotic, death-receptor inhibitor and complement inhibitor. Exact P values are given beside each bar, in black where P < 0.05 and in gray otherwise. Because the comparator cells are matched on sequencing depth, these are compositional comparisons: a gene is elevated relative to the rest of the transcriptome in the same cells, and a uniform increase in transcriptional output would not register as a difference. P values are from a one-sample two-sided t-test on per-library log₂ fold changes (n = 11 libraries). d , In vitro cytotoxicity of the anti-CD20 mAbs rituximab, obinutuzumab and ocrelizumab, the anti-CD19 mAb inebilizumab, CD19-CAR T cells, and the CD19 T-cell engager blinatumomab (CD19 × CD3), against EBV⁻ targets (primary B cells and Ramos cells) and EBV⁺ lymphoblastoid cell lines (LCL-1 and LCL-2) across NK cell, CAR T-cell, or T cell effector-to-target ratios. Anti-CD20 and anti-CD19 antibodies showed reduced cytotoxicity against EBV⁺ relative to EBV⁻ targets at every ratio, whereas CD19-CAR T cells and blinatumomab differed only at the intermediate 2:1 ratio. Data are mean ± s.e.m.; differences between EBV⁺ and EBV⁻ targets were assessed by two-way analysis of variance with Sidak’s correction, with exact P values shown at each ratio and ns denoting P ≥ 0.05.

    Article Snippet: T cells were depleted from PBMCs by magnetic-activated cell sorting (MACS) using CD3 MicroBeads (Cat#130-050-101; Miltenyi Biotec).

    Techniques: Quantitative Proteomics, Labeling, Sequencing, In Vitro, Analysis, Bioprocessing

    ( A-C ) Flow cytometry analysis of CD3 + and CD11b + fractions using the indicated antibodies. ( D-F ) Representative images (bottom) show microglia, CD3 + T cells, and splenic myeloid cells 7 days after culture following isolation from the brain and spleen (Scale: 20x). Abbreviations: SMCs = spleen myeloid cells; MG = microglia. Please click here to view a larger version of this figure .

    Journal: Journal of visualized experiments : JoVE

    Article Title: Isolation of Brain Microglia to Study Persistence of Human Immunodeficiency Virus-1

    doi: 10.3791/71673

    Figure Lengend Snippet: ( A-C ) Flow cytometry analysis of CD3 + and CD11b + fractions using the indicated antibodies. ( D-F ) Representative images (bottom) show microglia, CD3 + T cells, and splenic myeloid cells 7 days after culture following isolation from the brain and spleen (Scale: 20x). Abbreviations: SMCs = spleen myeloid cells; MG = microglia. Please click here to view a larger version of this figure .

    Article Snippet: CD3 MicroBead Kit, non-human primate , Miltenyi Biotec , Cat# 130-092-012 , .

    Techniques: Isolation, Flow Cytometry, Analysis